Academic Journal
HCV treatment in children and young adults with HIV/HCV co-infection in Europe
| Title: | HCV treatment in children and young adults with HIV/HCV co-infection in Europe |
|---|---|
| Authors: | Anna Turkova, Vania Giacomet, Tessa Goetghebuer, Milana Miloenko, Laura Ambra Nicolini, Antoni Noguera-Julian, Pablo Rojo, Alla Volokha, Giuseppe Indolfi, Carlo Giaquinto, Claire Thorne |
| Source: | Journal of Virus Eradication, Vol 1, Iss 3, Pp 179-184 (2015) |
| Publisher Information: | Elsevier, 2015. |
| Publication Year: | 2015 |
| Collection: | LCC:Microbiology LCC:Public aspects of medicine |
| Subject Terms: | HCV/HIV co-infection, pegylated interferon, ribavirin, children, young people, Microbiology, QR1-502, Public aspects of medicine, RA1-1270 |
| More Details: | Objectives: To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children and young people living in Europe and to evaluate treatment outcomes. Methods: HCV treatment data on children and young people aged >25 years with HIV/HCV co-infection were collected in a cohort collaboration of 11 European paediatric HIV cohorts. Factors associated with receipt of HCV treatment and with sustained virological response 24 weeks after treatment completion (SVR24) were explored. Results: Of 229 HIV/HCV co-infected patients, 22% had a history of AIDS and of 55 who were treated for HCV, 47 (85%) were receiving combined antiretroviral therapy. The overall HCV treatment rate was 24% (n=55) but it varied substantially between countries, with the highest rate being in Russia at 61% (30/49). Other factors associated with treatment receipt were older age [adjusted odds ratio (AOR) 5.24, 95% confidence interval (CI) 1.9–14.4, for 18–24-year-olds vs 11–17-year-olds, P=0.001] and advanced fibrosis (AOR 5.5, 95% CI 1.3–23.7; for ≥9.6 vs ≤7.2 kPa, P=0.02). Of 50 patients with known treatment outcomes, 50% attained SVR24. Of these, 16 (80%) had genotype (GT) 2,3 and 8 (29%) had GT 1,4 (P>0.001). After adjusting for genotype (GT 1,4 vs GT 2,3), females (P=0.003), patients with non-vertical HCV acquisition (P=0.002) and those with shorter duration of HCV (P=0.009) were more likely to have successful treatment outcomes. Conclusion: Only half of the HIV/HCV co-infected youth achieved an HCV cure. HCV treatment success appears to be lower in the context of HIV co-infection than in HCV mono-infection, underscoring the urgent need to speed up approvals of new direct-acting antiviral combinations in children. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2055-6640 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2055664020305045; https://doaj.org/toc/2055-6640 |
| DOI: | 10.1016/S2055-6640(20)30504-5 |
| Access URL: | https://doaj.org/article/ebc00179a9a74bcdb7005b3f0e55956c |
| Accession Number: | edsdoj.bc00179a9a74bcdb7005b3f0e55956c |
| Database: | Directory of Open Access Journals |
| ISSN: | 20556640 |
|---|---|
| DOI: | 10.1016/S2055-6640(20)30504-5 |
| Published in: | Journal of Virus Eradication |
| Language: | English |